Which Filler Goes Where — and Why the Brand Matters Less Than the Plane

The brand on the syringe is the least useful thing about a filler treatment. What decides how it looks, how long it lasts and whether it can be undone is which region it went into and which layer it was placed in. Here is the map.

Last reviewed 15 September 2026Reviewed quarterly
HA fillerBiostimulatorSculptraOverfilled faceDissolving filler
Filler regions of the face and the plane each is treated inA front view of a face with eight injectable regions marked: Temple, treated deep, on the bone beneath the temporalis fascia; Lateral cheek, treated deep, directly on the zygomatic bone; Medial cheek, treated deep to the superficial fat, above the periosteum; Tear trough, treated deep, on the bone under the orbicularis muscle. never superficial.; Nasolabial fold, treated deep to the fold itself, not into it; Lips, treated submucosal, in the body of the lip and along the vermilion border; Jawline and prejowl, treated deep, on the mandible; Chin, treated deep, on the bone in the midline. The point of the map is that the plane a product is placed in changes how it behaves more than the brand on the box does.12345678Region and plane1TempleDeep, on the bone2Lateral cheekDeep, on the zygomatic bone3Medial cheekDeep to the superficial fat4Tear troughDeep, on the bone. Never superficial5Nasolabial foldDeep to the fold, not into it6LipsSubmucosal, in the body of the lip7Jawline and prejowlDeep, on the mandible8ChinDeep, on the bone in the midline
Where product goes, and in which plane. Regions on the cheek and jaw are drawn on one side for clarity; the lips and chin are shown across the midline. The interactive version of this map is at /tools/filler-map.Illustration: facelove.info
Jump to

Almost every consultation about filler starts with a brand name. Someone read about a product, or a friend had it, or a clinic advertises it. I understand why. The brand is the only part of the treatment that gets marketed to you.

It is also the part that changes the result least.

Two people can be injected with the identical gel from the identical box and walk out looking completely different, because one had it placed deep on the cheekbone and the other had it placed superficially under the eye. Same molecule. Different plane, different region, different treatment. If you learn one thing before you sit in an injector's chair, learn to ask where the product is going and how deep.

What the plane changes

Filler sits in a layer, and each layer behaves differently.

Placed deep, on bone, a stiff gel acts as structure. It supports the tissue above it, it moves very little, and it holds its shape when you smile. Placed superficially, in or just under the skin, the same material has to bend every time your face moves, and it shows through thin skin as a shadow or a blue-gray cast.

That is why the honest version of the filler conversation is anatomical. The useful question is not which product you want. It is which region has actually lost support, and which layer that support belongs in.

Region by region

The map above is the working version of what I sketch on paper in the room. Eight regions, each with its own plane, its own realistic longevity, and its own way of going wrong.

A few things worth pulling out of it.

The lateral cheek does the most work. Product placed deep on the zygomatic bone supports the whole midface. It is often the region that fixes a complaint about somewhere else entirely: the nasolabial fold, the under-eye, the jawline. Those are shadows cast by a midface that has descended and deflated.

The tear trough is the least forgiving region on the face. Skin there is thinner than anywhere else, the product binds water, and the margin between a correction and a permanent puffiness is small. It is also the region where product persists longest. I have dissolved filler placed under someone's eyes five years earlier.

The nasolabial fold is usually a symptom. The fold deepens because the cheek above it fell. Filling the fold treats the shadow and leaves the cause alone, which is why the result so often reads as heavy.

Filler defines a jawline. It does not lift a jowl. Past a certain amount of laxity, product along the mandible makes the jowl more conspicuous, because you have drawn a hard line underneath it.

Stiffness is a placement decision, not a quality ranking

Gels are described by how much force it takes to deform them. High-stiffness gels hold shape and resist the pressure of the tissue above them, which is what you want on bone. Low-stiffness gels spread and move, which is what you want in a lip.

Neither is better. A stiff gel in a lip looks like a sausage. A soft gel on a cheekbone disappears into the tissue and does nothing, and then someone recommends more syringes.

The same logic covers biostimulators — poly-L-lactic acid, dilute calcium hydroxylapatite. Those are not fillers in the ordinary sense. They deposit a material your body responds to by making collagen, so the result arrives over months and leaves over years. That is a genuinely different treatment with a genuinely different risk profile, and it belongs in a different conversation from a hyaluronic acid gel.

Reversibility is real, and it is not absolute

Hyaluronic acid dissolves. Hyaluronidase breaks it down within a day or two, and that is a meaningful safety feature — it is what makes a vascular complication treatable, and it is why I use HA in the regions where the consequences of getting it wrong are highest.

Two caveats.

Dissolving is not free. Hyaluronidase is not perfectly selective, and the tissue takes weeks to settle afterward. Nobody should treat reversibility as a license to over-treat and undo it later.

And calcium hydroxylapatite and poly-L-lactic acid do not dissolve. If you are having a biostimulator placed in your jawline or your chin, you are making a decision you cannot take back for a year or more. That is not an argument against them. It is an argument for placing them conservatively.

What overfilling actually looks like

This is the part that is hardest to find written down, so here it is plainly. Each region fails in its own characteristic way.

  • Temples. A convex shine above the brow where there should be a gentle hollow, and an upper face that has quietly got wider.
  • Lateral cheek. The shelf. A hard horizontal ledge high on the cheek that catches the light, eyes that look smaller, a face that widens on smiling.
  • Medial cheek. Pillowing. It reads as puffiness, and people around you will describe you as looking tired or as having gained weight.
  • Tear trough. A bluish-gray fullness that is worse in the morning and never quite resolves.
  • Lips. A flattened white roll, a visible step in the gel when you smile, and an upper lip that projects further forward than the lower one in profile. The side view is the honest one.
  • Jaw and chin. A heavy, squared lower face, and a chin that hangs slightly forward of the jaw when you look down.

None of these happen in one appointment. They happen over years, half a syringe at a time, and they happen because each individual appointment was defensible on its own.

How I think about it in the room

I sort a face into three questions before anyone touches a syringe.

What has descended? That is a lifting problem, and product does not answer it.

What has deflated? That is a volume problem, and where it is deflated tells me which plane the volume belongs in.

What is simply the shape of your face? Some of what people want to fill is anatomy, not aging, and filling it changes who you look like.

Most faces are a mix of all three in a proportion specific to that face. Sorting out which is which is the entire value of a consultation, and it is why a plan that starts with a product name has the sequence backwards.

Questions worth asking before anyone injects you

Four, and they take a minute.

  1. Which region are you treating, and which layer are you placing this in?
  2. Is this hyaluronic acid, and if it is not, what is the plan if I dislike it?
  3. What will this look like in three years if I keep doing it at this interval?
  4. What are you deliberately choosing not to treat today, and why?

The fourth one is the most useful question on the list. An injector who has a clear answer to it is thinking about your face over a decade. An injector who treats everything you point at is thinking about today.

The verdicts on this

All verdicts
ModestEvidence grade CSkin & Prevention

Injectable Skin Boosters

A real, measurable improvement in skin hydration and fine texture that fades on a predictable schedule.

Last reviewed 15 September 2026

Thin evidenceEvidence grade CFacelift & Neck

PDO Thread Lifts

A small, short-lived repositioning effect that is consistently oversold as an alternative to surgery.

Last reviewed 15 September 2026

Recent coverage

All news
NewsInjectables2 September 2026

Twelve-Month Data on a Poly-L-Lactic Acid Biostimulator

A prospective multicenter study in the Aesthetic Surgery Journal followed patients treated with a next-generation poly-L-lactic acid biostimulator in the nasolabial folds for a year, reporting effectiveness, satisfaction and safety. Biostimulators are a different treatment from hyaluronic acid rather than a longer-lasting version of it: they deposit a material the body answers by making collagen, so the result builds over months and fades over years. Durability data therefore matters more here than it does for a gel that dissolves.

Aesthetic surgery journal, “Effectiveness, Patient Satisfaction, and Safety of a Next-generation PLLA Collagen Biostimulator for Nasolabial Fold Augmentation: 12-month Results of a Prospective Multicenter Study.” — read the original

NewsInjectables30 August 2026

Five Decades of Filler Lawsuits, and Where They Land

A review in the Aesthetic Surgery Journal examined forty-six U.S. civil cases involving injectable fillers between 1967 and 2025. Verdicts split almost evenly overall, and autologous fat, hyaluronic acid and biostimulators were implicated in roughly equal numbers. Two findings stand out: cases arising from med-spa procedures produced a plaintiff verdict every time, against forty-seven percent in private clinics and hospitals, and cases involving products without regulatory approval did the same. Neither the injector's credentials nor the severity of the complication predicted the outcome on its own.

Aesthetic surgery journal, “Litigating Filler Complications: Five Decades of Legal Outcomes in the United States.” — read the original

Related guides

All guides
GuideVolume & Fat Transfer

GLP-1 Weight Loss and the Face: What Empties, and What Puts It Back

The medication is not damaging your face. Fast weight loss is, and it does it through discrete fat compartments that empty at different rates. That mechanism decides which treatments can realistically restore it.

Last reviewed 15 September 2026

GuideFacelift & Neck

Deep Plane or SMAS: What Actually Differs, and Who Each One Suits

Both operations are called facelifts and both are done by good surgeons. The difference is which anatomical layer carries the lift, and that one decision changes the look, the durability, the scar and the risk profile.

Last reviewed 15 September 2026

Newsletter

The one email a week that isn't selling you something.

What changed in facial rejuvenation this week, one guide we updated, and why it matters. Written by Jay Keni, MD.

A weekly email, once we launch it. We don’t sell or share addresses, and we never add patients from practice records — privacy.

Found something out of date, or something we got wrong? How we handle corrections.